Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 4/20 | 0.50 |
| ▸ | CPA3 | P15088 | 2/20 | 0.50 |
| ▸ | CPB1 | P15086 | 1/20 | 0.50 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.35 |
| ▸ | PPARG | P37231 | 3/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 2/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.34 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4463457 | 1.00 | CPA1 (0.50) | CPA1CPA3CPB1CPB2FOLH1 | |
| SCHEMBL4478582 | 0.92 | CPA1 (0.45) | CPA1CPA3CPB1CPB2FOLH1 | |
| SCHEMBL4461700 | 0.92 | CPA1 (0.45) | CPA1CPA3CPB1CPB2FOLH1 | |
| SCHEMBL3520174 | 0.90 | CPA1 (0.44) | CPA1CPA3CPB1CPB2FOLH1 | |
| SCHEMBL3520168 | 0.90 | CPA1 (0.44) | CPA1CPA3CPB1CPB2FOLH1 | |
| SCHEMBL3306650 | 0.85 | FOLH1 (0.37) | CPA1CPA3CPB1CPB2FOLH1 | |
| SCHEMBL3306655 | 0.85 | FOLH1 (0.37) | CPA1CPA3CPB1CPB2FOLH1 | |
| SCHEMBL3520209 | 0.80 | CPA1 (0.45) | CPA1CPA3CPB1CPB2FOLH1 | |
| SCHEMBL3520214 | 0.80 | CPA1 (0.45) | CPA1CPA3CPB1CPB2FOLH1 | |
| SCHEMBL4456537 | 0.80 | GRB2 (0.50) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595312-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-09-29 | — | — | US | disclosed |
| US-20060079504-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079504-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | CPA1 653/4885CPA3 299/4885CPB1 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.